Rathbones Group’s Autolus Therapeutics AUTL Stock Holding History

Rathbones Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.9K	Hold	28,050	–	–	﹤0.01%	658
2026 Q1	$38.7K	Sell	28,050 -36,950	-57%	-$56.1K	﹤0.01%	638
2025 Q4	$129K	Hold	65,000	–	–	﹤0.01%	597
2025 Q3	$106K	Hold	65,000	–	–	﹤0.01%	612
2025 Q2	$148K	Hold	65,000	–	–	﹤0.01%	572
2025 Q1	$101K	Hold	65,000	–	–	﹤0.01%	560
2024 Q4	$153K	Sell	65,000 -2,300	-3%	-$7.78K	﹤0.01%	550
2024 Q3	$244K	Hold	67,300	–	–	﹤0.01%	519
2024 Q2	$234K	Hold	67,300	–	–	﹤0.01%	529
2024 Q1	$429K	Sell	67,300 -2,000	-3%	-$12.5K	﹤0.01%	435
2023 Q4	$446K	Sell	69,300 -4,000	-5%	-$15.3K	﹤0.01%	418
2023 Q3	$171K	Buy	+73,300	New	+$209K	﹤0.01%	551

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rathbones Group's AUTL Position: Q2 2026 in Review

Rathbones Group held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 28,050 shares worth $44.9K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Rathbones Group first reported a position in AUTL in Q3 2023 and has held it in 12 quarters since. The position peaked at $446K in Q4 2023. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Rathbones Group held 28,050 shares of Autolus Therapeutics worth $44.9K as of Q2 2026.
Rathbones Group left its Autolus Therapeutics share count unchanged in Q2 2026.
Autolus Therapeutics made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #658 holding.
Rathbones Group first reported a position in Autolus Therapeutics in Q3 2023 and has held it in 12 quarters since.
Rathbones Group's Autolus Therapeutics position peaked at $446K in Q4 2023.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.